37 results on '"Zhan, Zhirong"'
Search Results
2. Data from Upregulation of ABCG2 by Romidepsin via the Aryl Hydrocarbon Receptor Pathway
3. Supplementary Figure 2 from Upregulation of ABCG2 by Romidepsin via the Aryl Hydrocarbon Receptor Pathway
4. Supplementary Figure 1 from Upregulation of ABCG2 by Romidepsin via the Aryl Hydrocarbon Receptor Pathway
5. Supplementary Figure Legends from Upregulation of ABCG2 by Romidepsin via the Aryl Hydrocarbon Receptor Pathway
6. Supplementary Data from Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2
7. MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor
8. Designing porous and stable Au coating Ni nanosheets based Ni foam for quasi-symmetric polymer Li–air Batteries
9. Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer
10. Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma
11. Resistance to paclitaxel mediated by P-glycoprotein can be modulated by changes in the schedule of administration
12. Low Concentrations of the Histone Deacetylase Inhibitor, Depsipeptide (FR901228), Increase Expression of the Na+/I− Symporter and Iodine Accumulation in Poorly Differentiated Thyroid Carcinoma Cells
13. Construction of Gene Therapy Vectors Targeting Adrenocortical Cells: Enhancement of Activity and Specificity with Agents Modulating the Cyclic Adenosine 3′,5′-Monophosphate Pathway
14. Downregulation of mdr-1 Expression by 8-Cl-cAMP in Multidrug Resistant MCF-7 Human Breast Cancer Cells
15. Measuring MDR-1 by Quantitative RT-PCR
16. Loss of the proteins Bak and Bax prevents apoptosis mediated by histone deacetylase inhibitors
17. Abstract 3399: Resistance to the histone deacetylase inhibitor romidepsin is associated with degradation of Bim following MAPK pathway activation.
18. Histone deacetylase inhibitors induce CXCR4 mRNA but antagonize CXCR4 migration
19. Histone Deacetylase Inhibitors: Emerging Mechanisms of Resistance
20. The Challenge of Exploiting ABCG2 in the Clinic
21. Upregulation of ABCG2 by Romidepsin via the Aryl Hydrocarbon Receptor Pathway
22. Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2
23. Regulation of ABCG2 Expression at the 3′ Untranslated Region of Its mRNA through Modulation of Transcript Stability and Protein Translation by a Putative MicroRNA in the S1 Colon Cancer Cell Line
24. Increased MDR1 Expression in Normal and Malignant Peripheral Blood Mononuclear Cells Obtained from Patients Receiving Depsipeptide (FR901228, FK228, NSC630176)
25. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance
26. Use of peptide antibodies to probe for the mitoxantrone resistance-associated protein MXR/BCRP/ABCP/ABCG2
27. Low Concentrations of the Histone Deacetylase Inhibitor, Depsipeptide (FR901228), Increase Expression of the Na+/I−Symporter and Iodine Accumulation in Poorly Differentiated Thyroid Carcinoma Cells
28. Genetic Polymorphism in MDR-1: A Tool for Examining Allelic Expression in Normal Cells, Unselected and Drug-Selected Cell Lines, and Human Tumors
29. Like p53, the Proliferation-Associated Protein p120 Accumulates in Human Cancer Cells Following Exposure to Anticancer Drugs
30. Paclitaxel-resistant Human Ovarian Cancer Cells Have Mutant β-Tubulins That Exhibit Impaired Paclitaxel-driven Polymerization
31. Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression
32. Expression of the Multidrug Resistance-Associated Protein Gene in Refractory Lymphoma: Quantitation by a Validated Polymerase Chain Reaction Assay
33. Clinical Reversal of Multidrug Resistance
34. Measuring MDR-1 by Quantitative RT-PCR.
35. Expression of mdr-1 in Refractory Lymphoma: Quantitation by Polymerase Chain Reaction and Validation of the Assay
36. [Nasal mucosa remodeling in chronic rhinosinusitis without nasal polyps].
37. The challenge of exploiting ABCG2 in the clinic.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.